Cerebrotendinous Xanthomatosis (CTX) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Cerebrotendinous xanthomatosis (CTX) is a lipid storage disorder characterized by a spectrum of clinical manifestations starting from early infancy to adulthood. Initial symptoms often include chronic diarrhea or neonatal cholestasis. Childhood-onset cataracts are common, typically appearing within the first decade of life in about 75% of affected individuals. Tendon xanthomas, predominantly in the second or third decade, manifest as deposits on various tendons such as the Achilles, extensor tendons of the elbow and hand, patellar tendon, and neck tendons. Xanthomas have also been reported in other organs, including the lungs, bones, and central nervous system. Neurological symptoms progress with age, starting with cognitive impairment in some cases from infancy, while others maintain normal intellectual function until puberty. Dementia becomes prevalent by the third decade in more than half of patients, often accompanied by psychiatric disturbances such as behavioral changes, hallucinations, and mood disorders. Neurological signs such as spasticity and cerebellar dysfunction typically appear between 20 and 30 years old. Diagnosis of CTX involves identifying biallelic pathogenic variants in the CYP27A1 gene through genetic testing in individuals with suggestive clinical features. Treatment options include long-term chenodeoxycholic acid (CDCA) administration, which normalizes cholestanol levels in plasma and cerebrospinal fluid (CSF) and improves neurophysiological findings. HMG-CoA reductase inhibitors, either alone or in combination with CDCA, are also effective but may pose risks of muscle damage. Cholic acid has shown promise in reducing cholestanol levels and alleviating neurological symptoms in some patients intolerant to CDCA. Progressive in nature, CTX significantly impacts life expectancy if untreated, with survival typically in the fifth or sixth decades. However, early intervention, particularly before neurological deterioration, can extend life expectancy to near-average levels. Treatment strategies also include surgical management of cataracts and symptomatic relief for epilepsy, spasticity, and parkinsonism.

Thelansis’s “Cerebrotendinous Xanthomatosis (CTX) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebrotendinous Xanthomatosis (CTX) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cerebrotendinous Xanthomatosis (CTX) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cerebrotendinous Xanthomatosis (CTX) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Cerebrotendinous Xanthomatosis (CTX) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033